Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina, Bernard M., Susan C. Fagan, Robert G. Hart, Collin A. Hovinga, Diane D. Murphy, Ted M. Dawson, and John R. Marler
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…  
  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…  
  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.